The measurement of glycated haemoglobin (as HbA1c ) is central to diabetes care. This is the measure by which health-care providers can relate blood glucose control to the risk of complications, such as eye damage or kidney failure. However, a lack of standardization in the methods used to measure glycated haemoglobin has produced wide variations among results and is among the current limitations to the effective use of HbA1c results in gauging a person’s risk of these complications. Jean-Claude Mbanya reports on the efforts of a group – which includes members from the International Diabetes Federation (IDF), the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) – to respond to the need for a more universally applicable method for measuring and reporting glycated haemoglobin.
glycated haemoglobin, HBA1C, DCCT, UKPDS, standardization, assay, ADA, EASD, IFCC, mean blood glucose, MBG